The up-regulation of miR-709 enhanced the levels of β-catenin while reducing the expression of inflammatory cytokines IL-1β, IL-6 and TNFα, all known to be up-regulated in IBM patients [119]. The gene discussed is IL6; the disease is inclusion body myositis.